In patients with type-2 diabetes, hyperglycemia reduces the level of VEGF and SDF-1 secretion from endothelial cells via the hypoxia-inducible factor/hypoxia-response element pathway and dipeptidyl peptidase-4 activity [162], therefore decreasing the mobilization of EPCs from bone marrow to circulation [163,164] and impairing the regulation of growth, migration and survival of EPCs [165]. The gene discussed is VEGFA; the disease is Hyperglycemia.